<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The INK4a-ARF [CDKN2A]- locus on chromosome 9p21 encodes for two <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor proteins, p16INK4a and p14ARF, which act as upstream regulators of the Rb-CDK4 and p53 pathways </plain></SENT>
<SENT sid="1" pm="."><plain>To study the contribution of each pathway to the <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> of Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, we analysed the alterations of p14ARF and p16INK4a in preneoplastic and neoplastic lesions of this disease </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIALS AND METHODS: After microdissection, DNA of 15 Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, 40 Barrett's intraepithelial <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (n=20 low- and n=20 high-grade) and 15 Barrett's mucosa without <z:hpo ids='HP_0002664'>neoplasia</z:hpo> was analysed for INK4-ARF inactivation using DNA sequence and loss of heterozygosity (LOH) analysis, methylation-specific polymerase chain reaction, restriction-enzyme-related polymerase chain reaction and immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: We detected 9p21 LOH, p16INK4a methylation and p16INK4a mutations in Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> in 5 of 15 (33%), 8 of 15 (53%) and 1 of 15 (7%) patients, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>P14ARF was methylated in 3 of 15 (20%) <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>In Barrett's intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, p16INK4a was altered in 12 of 20 (60%) high-grade and in 4 of 20 (20%) low-grade intraepithelial <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In Barrett's mucosa without intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> p16(INK4a) was methylated in one case (7%) </plain></SENT>
<SENT sid="7" pm="."><plain>P14ARF was intact in Barrett's mucosa without intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: We conclude that most Barrett's intraepithelial <z:hpo ids='HP_0002664'>neoplasms</z:hpo> contain genetic and/or epigenetic INK4a-ARF alterations </plain></SENT>
<SENT sid="9" pm="."><plain>Methylation of p16INK4a appears to be the most frequent epigenetic defect in the <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> of Barrett's <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">tumourigenesis</z:e> </plain></SENT>
</text></document>